An Escalating Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of LNK 754 in Elderly Volunteers and in Subjects With Mild Alzheimer's Disease
NCT01013610
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
110
Enrollment
INDUSTRY
Sponsor class
Conditions
Mild Alzheimer's Disease
Interventions
DRUG:
LNK-754
DRUG:
Placebo
Sponsor
Link Medicine Corporation